Zymfentra Alternatives Compared
| Zymfentra (infliximab) | Humira (adalimumab) | Entyvio (vedolizumab) |
|
|---|
| Zymfentra (infliximab) | Humira (adalimumab) | Entyvio (vedolizumab) |
|
|||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Prescription only
Prescribed for Ulcerative Colitis, Crohn's Disease, Inflammatory Bowel Disease, Crohn's Disease - Maintenance, Ulcerative Colitis - Maintenance. Zymfentra may also be used for purposes not listed in... View more |
Prescription only
Humira is a TNF-alfa inhibitor that may be used to treat a wide range of different inflammatory conditions, such as Rheumatoid Arthritis, psoriasis, ankylosing spondylitis, Crohn's disease, and... View more |
Prescription only
Entyvio infusion is an integrin receptor antagonist that may be used to reduce inflammation associated with moderate to severe ulcerative colitis or Crohn's disease. It targets the gut specifically... View more |
Related suggestions Ulcerative Colitis
Crohn's Disease
Crohn's Disease, Maintenance
|
|||||||||||||||
| More about Zymfentra (infliximab) | More about Humira (adalimumab) | More about Entyvio (vedolizumab) | ||||||||||||||||
| Ratings & Reviews | ||||||||||||||||||
|
Be the first to share your experience with this drug. |
Humira has an average rating of 6.4 out of 10 from a total of 704 ratings on Drugs.com. 55% of reviewers reported a positive effect, while 30% reported a negative effect. |
Entyvio has an average rating of 6.3 out of 10 from a total of 167 ratings on Drugs.com. 49% of reviewers reported a positive effect, while 28% reported a negative effect. |
||||||||||||||||
| Side Effects Experienced by Users Side effects are reported in Drugs.com user reviews and not clinically verified. | ||||||||||||||||||
|
View all Zymfentra side effects |
View all Humira side effects |
View all Entyvio side effects |
||||||||||||||||
| Drug Class | ||||||||||||||||||
| Generic Availability | ||||||||||||||||||
|
N/A |
N/A |
N/A |
||||||||||||||||
| Pricing and Coupons * Prices are without insurance | ||||||||||||||||||
|
We could not find an exact match for this medicine. Try searching the Price Guide directly. |
View all Humira prices |
View all Entyvio prices |
||||||||||||||||
| Dosage Forms | ||||||||||||||||||
|
N/A |
|
|
||||||||||||||||
| Brand Names | ||||||||||||||||||
| Other infliximab brands include: Avsola, Inflectra, Ixifi, Remicade, Renflexis | Other adalimumab brands include: Abrilada, Amjevita, Cyltezo, Hadlima, Hulio, Hyrimoz, Idacio, Simlandi, Yuflyma, Yusimry View more | Other vedolizumab brands include: Entyvio Pen | ||||||||||||||||
| Half Life Drug half-life is the time required for plasma concentration to reduce to half its original value. | ||||||||||||||||||
|
228 hours |
480 hours |
600 hours |
||||||||||||||||
| CSA Schedule 1 View glossary of CSA terms | ||||||||||||||||||
|
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||||||||||
| Pregnancy Category | ||||||||||||||||||
|
Category B
No proven risk in humans
See the full pregnancy warnings document. |
Category B
No proven risk in humans
See the full pregnancy warnings document. |
Category B
No proven risk in humans
See the full pregnancy warnings document. |
||||||||||||||||
| Drug Interactions | ||||||||||||||||||
|
A total of 572 drugs are known to interact with Zymfentra:
|
A total of 556 drugs are known to interact with Humira:
|
A total of 170 drugs are known to interact with Entyvio:
|
||||||||||||||||
| Alcohol/Food/Lifestyle Interactions | ||||||||||||||||||
|
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
||||||||||||||||
| Disease Interactions | ||||||||||||||||||
| First Approval Date | ||||||||||||||||||
|
October 20, 2023 |
December 31, 2002 |
May 20, 2014 |
||||||||||||||||
| WADA Class View classifications | ||||||||||||||||||
|
N/A |
N/A |
N/A |
||||||||||||||||
| More Information | ||||||||||||||||||
| Patient Resources | ||||||||||||||||||
| Professional Resources | ||||||||||||||||||
| Related Treatment Guide | ||||||||||||||||||
1 The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
See also:
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.